Chronic myeloid leukemia (CML) starts in the blood-forming cells in the bone marrow and spreads to the blood. The symptoms and treatment options can vary according to the stage of CML. Share on ...
Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study ...
The BCR/ABL fusion gene originating from a t(9;22)(q34;q11.2) chromosomal translocation is the molecular marker of chronic myeloid leukemia (CML). In the vast majority of CML cases the breakpoint on ...
More news from the American Society of Hematology meeting: In the first head-to-head comparison of Novartis' Tasigna and its older medicine Glivec (also known as Gleevec), Tasigna results showed ...
Jian-Hua Mao, Xiao-Yan Sun, Jian-Xiang Liu, Qun-Ye Zhang, Ping Liu, Qiu-Hua Huang, Keqin Kathy Li, Quan Chen, Zhu Chen, Sai-Juan Chen Proceedings of the National Academy of Sciences of the United ...
June 20, 2011 (London, United Kingdom) — With 24 months of follow-up, nilotinib continues to show superiority over imatinib for the treatment of newly diagnosed patients with chronic myeloid leukemia ...
ZURICH, Oct 20 (Reuters) - Swiss drugmaker Novartis AG's Tasigna drug met its main target in a late-stage, head-to-head trial against the company's Glivec as a first line treatment against chronic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback